Table 3.

Characteristics of the IL-1 inhibitors used for the treatment of sJIA.

	Dosage	Route of administration	Half-life
Anakinra	1–4 mg/kg/day	Subcutaneous	4–6 h
Canakinumab	≥2 years: 4 mg/kg/dose q 4 weeks	Subcutaneous	23–26 days
	Maximum dose: 300 mg
Rilonacept	Starting dose 4.4 mg/kg, then 2.2 mg/kg/week	Subcutaneous	1 week
	Maximum loading dose: 320 mg
	Maximum weekly dose: 160 mg/week